Tata Elxsi Awarded Global Services Deal from Aesculap AG for Medical Device Engineering

October 28, 2020

Tata Elxsi, a global design and technology services company, announces the opening of a Global Engineering Center (GEC) with Aesculap AG, a subsidiary of B. Braun, one of the world´s leading manufacturers of medical devices and pharmaceutical products and services.

Tata Elxsi has been selected as the global engineering services partner by Aesculap. The GEC is part of a strategic multi-year engagement in the field of engineering services.

The GEC serves as a platform of talent and expertise for product design & engineering, regulatory support, and clinical evaluation services. This center will be essential to accelerate innovation, drive the transformation and growth for Aesculap’s medical business.

Martin Schaeuble, Vice President Abdominal and Cardio-Thoracic Surgery, Aesculap commented on this announcement, Tata Elxsi has proven to be the right partner, bringing the right mix of technical expertise and program management skills. Together with Tata Elxsi, we are in the position to continue our innovation activities as well as adherence across Aesculap ‘s product portfolio.”

“We are elated to be selected as a strategic partner of Aesculap. It is an absolute honor for us to be part of this journey in supporting Aesculap through our Global Engineering Center, bringing together integrated competencies in R&D and innovation, digital technologies, deep domain understanding of medical devices and ever-evolving regulatory standards. This further consolidates our position in the Medical Devices and Healthcare market in Europe, and strengthens our relationship with Aesculap and the B. Braun group,” said Nitin Pai, Chief Strategy Officer and CMO, Tata Elxsi.

Earlier this month, the company was selected as certified 3PL partner for Google Widevine.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version